<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01442792</url>
  </required_header>
  <id_info>
    <org_study_id>15572</org_study_id>
    <secondary_id>2011-001094-58</secondary_id>
    <nct_id>NCT01442792</nct_id>
  </id_info>
  <brief_title>Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention</brief_title>
  <acronym>X-PLORER</acronym>
  <official_title>Prospective, Multi-center, Randomized, Heparin-controlled Dose-finding Trial to Evaluate the Efficacy and Safety of Rivaroxaban, a Direct Factor Xa Inhibitor, on the Background of Standard Dual Antiplatelet Therapy to Support Elective Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Balloon angioplasty (Percutaneous Coronary Intervention (PCI)) is commonly used to treat
      patients with obstructive coronary artery disease (CAD). Although PCI is highly effective for
      the management of CAD, it can potentiate an existing prothrombotic state around lesion areas.
      A certain level of anticoagulation is required to perform planned PCI safely and to minimize
      the periprocedural risk of thrombosis and its attendant complications, including myocardial
      ischemia and infarction (heart attack). Many different anti-thrombotic regimens have been
      investigated and are currently in use. The aim of this study is to explore whether
      Rivaroxaban, as compared to unfractionated heparin, on the background of standard dual
      antiplatelet therapy, can effectively suppress thrombosis and related adverse ischemic
      events, upon balloon inflation and stent expansion, during elective PCI, without increasing
      bleeding. The treatment assignment will be done in a semi-blinded design, eg, no blinding for
      randomization either to Rivaroxaban (one of the three arms) or the control (UFH) group.
      However, all will be blinded for the treatment dose of rivaroxaban (either 10mg or 20 mg).The
      10 mg rivaroxaban plus 50 IU UFH arm will not be blinded.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of subjects who require bail-out anticoagulant therapy in the context of an ischemic coronary event</measure>
    <time_frame>During the index Percutaneous Coronary Intervention procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of subjects who experience an angiographic flow limiting thrombotic event</measure>
    <time_frame>During the index Percutaneous Coronary Intervention procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of subjects who experience thrombus formation on the Percutaneous Coronary Intervention equipment</measure>
    <time_frame>During the index Percutaneous Coronary Intervention procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of subjects who experience an Myocardial Infarction due to the Percutaneous Coronary Intervention equipment procedure</measure>
    <time_frame>During the index Percutaneous Coronary Intervention procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding (Thrombolysis in Myocardial Infarction major, minor and Bleeding academic research consortium type 2, 3 and 5)</measure>
    <time_frame>Up to 30 days post index Percutaneous coronary intervention procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of clinical ischemic events (all death, non-fatal Myocardial Infarction, non-fatal stroke and target lesion revascularization</measure>
    <time_frame>Up to 30 days post index Percutaneous coronary intervention procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation profile of Rivaroxaban (Activated Partial Thromboplastin Time)</measure>
    <time_frame>1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation profile of Rivaroxaban (Prothrombin time)</measure>
    <time_frame>1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation profile of Rivaroxaban (Thrombin Time)</measure>
    <time_frame>1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation profile of Rivaroxaban (Prothrombin Fragment 1+2)</measure>
    <time_frame>1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation profile of Rivaroxaban (Thrombin Anti-thrombin III Complexes)</measure>
    <time_frame>1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation profile of Rivaroxaban (Anti-Xa Activity)</measure>
    <time_frame>1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation profile of Rivaroxaban (endogenous thrombin potential)</measure>
    <time_frame>1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Rivaroxaban</measure>
    <time_frame>The day of percutaneous coronary intervention (PCI) (from 2 to 4 hours before to 6-8 hours after PCI)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Cardiovascular Disease, Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UFH</intervention_name>
    <description>Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>10 mg single dose Rivaroxaban (per os)</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>20 mg single dose Rivaroxaban (per os)</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939) and UFH</intervention_name>
    <description>10 mg single dose Rivaroxaban (per os) followed by bolus 50 IU/Kg unfractionated heparin (UFH)</description>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject aged 18 years or more with no upper age limit and willing to
             comply with the protocol

          -  Symptomatic coronary artery disease due to undergo an elective (non-emergent)
             Percutaneous Coronary Intervention (PCI) on one or two lesions in the native coronary
             vessel(s). Cardiac standard troponin at baseline is within the normal limits

        Exclusion Criteria:

          -  Conditions that may increase the risk of the PCI procedure

          -  Conditions that may increase the risk of bleeding

          -  Significant valvular heart disease

          -  Calculated creatinine clearance â‰¤30 mL/min

          -  Current use of anticoagulant drugs including Vitamin K antagonist (VKA), factor IIa or
             factor XA inhibitors

          -  Chronic treatment with non-steroidal anti-inflammatory drugs (NSAIDs)

          -  Chronic treatment with aspirin &gt; 100mg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zwolle</city>
        <zip>8011 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2011</study_first_submitted>
  <study_first_submitted_qc>September 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2011</study_first_posted>
  <last_update_submitted>January 19, 2017</last_update_submitted>
  <last_update_submitted_qc>January 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angioplasty, Balloon, Coronary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

